BioCentury
ARTICLE | Company News

Ultragenyx counters RegenxBio with bid for Dimension

September 18, 2017 9:30 PM UTC

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) offered to acquire gene therapy play Dimension Therapeutics Inc. (NASDAQ:DMTX) for $5.50 per share in cash, or about $138 million. Last month, RegenxBio Inc. (NASDAQ:RGNX) agreed to acquire Dimension in a stock deal with an implied value of $3.41 per Dimension share (see BioCentury Extra, Aug. 25).

Dimension jumped $1.70 (40%) to $5.90 on Monday. The company has added over $100 million in market cap since announcing its deal with RegenxBio...